• Home
  • The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.

The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.

Author List
Joshi SK, Pittsenbarger J, Kennedy VE, Peretz CAC, Perl AE, Smith CC, Tyner JW, Druker BJ, Traer E
Publication
American journal of hematology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/439145343
Publication Year
2023
PubMed ID
37815132
Publication Title
Joshi SK, Pittsenbarger J, Kennedy VE, Peretz CAC, Perl AE, Smith CC, Tyner JW, Druker BJ, Traer E. The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. Am J Hematol. 2023 12; 98(12):E364-E368.